A Phase 2 interventional study of Casdozokitug and Atezolizumab in Hepatocellular Carcinoma, sponsored by Coherus Oncology, Inc.. Terminated at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Coherus Oncology, Inc. · Phase 2, Interventional, and Treatment
How we know · 10 judgments
Sponsor decision
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 418th largest by enrollment of the 775 interventional ones that give a count, is one of 51 that started in 2022, is one of 259 in phase 2, and was the 763rd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 51 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
Coherus Oncology, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Coherus Oncology, Inc. has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
Only the Lead-In Phase of the study was completed.
This is a Phase 2 trial designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab (Arm A) compared to placebo in combination with atezolizumab plus bevacizumab (Arm B) in patients with first-line advanced or metastatic HCC.
After a Lead-In Phase of up to 30 patients who will receive open-label SRF388 + atezolizumab + bevacizumab, the blinded Randomized Phase will randomize approximately 104 patients with a 1:1 allocation to Arm A or Arm B and stratified by geographic region (Asia excluding Japan vs. rest of world) and Barcelona Clinic Liver Cancer (BCLC) stage (B or C).
Abbreviated Inclusion Criteria:
Abbreviated Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A minimum of 6 patients and up to 30 patients will be enrolled in an open-label Lead-In to assess the preliminary safety and tolerability of SRF388 with atezolizumab plus bevacizumab.
Drug: Casdozokitug · Drug: Atezolizumab · Drug: Bevacizumab
Patients randomized to Arm A will receive SRF388 with atezolizumab plus bevacizumab.
Drug: Casdozokitug · Drug: Atezolizumab · Drug: Bevacizumab
Patients randomized to Arm B will receive placebo with atezolizumab plus bevacizumab.
Drug: Atezolizumab · Drug: Bevacizumab · Drug: Placebo
Casdozokitug will be administered by intravenous injection (IV)
Also known as: CHS-388, SRF388
Atezolizumab will be administered by IV
Also known as: Tecentriq
Bevacizumab will be administered by IV
Also known as: Avastin
Placebo will be administered by IV
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as an AE that emerged or worsened in the period from the first dose of study drug to 30 days after the last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.
Time frame: Up to approximately 37 months
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
PFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to RECIST v1.1 or death due to any cause, whichever occured first. Disease progression was defined according to RECIST v1.1 criteria, including at least a 20% increase in the sum of diameters of target lesions relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 millimeters (mm), or the appearance of one or more new lesions.
Time frame: Up to approximately 38 months
PFS According to Hepatocellular Carcinoma Modified RECIST (HCC mRECIST) (mPFS)
mPFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to HCC mRECIST or death due to any cause, whichever occured first. Disease progression was defined per HCC mRECIST criteria, including at least a 20% increase in the sum of diameters of target lesions (including viable tumor diameters for typical intrahepatic target lesions and short axis diameters for nodal lesions) relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 mm.
Time frame: Up to approximately 38 months
Objective Response Rate (ORR) According to RECIST v1.1
ORR was defined as the percentage of participants achieving complete response (CR) and partial response (PR) per RECIST v1.1. * CR: Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to \< 10 mm in short axis. * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 38 months
ORR According to HCC mRECIST (mORR)
mORR was defined as the percentage of participants achieving complete response CR and PR per HCC mRECIST. * CR: Disappearance of any intratumoral arterial enhancement in all target lesions.. All pathological lymph nodes must have decreased to \< 10 mm in short axis. * PR: At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions. target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 38 months
Duration of Response (DoR) According to RECIST 1.1
DoR was defined as the time from first documentation of CR or PR until the time of the first documentation of PD evaluated using RECIST v1.1 or death due to any cause.
Time frame: Up to approximately 38 months
DoR According to HCC mRECIST (mDoR)
mDoR was defined as the time from first documentation of CR or PR until the time of the first documentation of PD evaluated using HCC mRECIST or death due to any cause.
Time frame: Up to approximately 38 months
Disease Control Rate (DCR) According to RECIST v1.1
DCR was defined as the percentage of participants who achieved CR, PR, or SD according to RECIST v1.1 for at least 12 weeks.
Time frame: Up to approximately 38 months
DCR According to HCC mRECIST (mDCR)
mDCR was defined as the percentage of participants who achieved CR, PR, or SD according to HCC mRECIST for at least 12 weeks.
Time frame: Up to approximately 38 months
Time to Progression (TTP) According to RECIST v1.1
TTP was defined as time from study drug initiation to the occurrence of disease progression per RECIST v1.1.
Time frame: Up to approximately 38 months
TTP According to HCC mRECIST (mTTP)
mTTP was defined as time from study drug initiation to the occurrence of disease progression per HCC mRECIST.
Time frame: Up to approximately 38 months
Overall Survival (OS)
OS was defined as the time from study drug initiation to death from any cause.
Time frame: Up to approximately 38 months
Time to Response (TTR) According to RECIST v1.1
TTR was defined as the time from study drug initiation to initial documented objective response per RECIST v1.1.
Time frame: Up to approximately 38 months
TTR According to HCC mRECIST (mTTR)
mTTR was defined as the time from study drug initiation to initial documented objective response per HCC mRECIST.
Time frame: Up to approximately 38 months
Time on Therapy
Time on therapy was defined as the time from study drug initiation to last treatment.
Time frame: Up to approximately 38 months
Mean Serum Epstein-Barr Virus Induced Gene 3 (EBI3) Concentration by Best Overall Response (BOR) According to RECIST v1.1
Baseline Serum EBI3 was collected and is reported by BOR status per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in the short axis to \<10 mm. * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.) * Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline up to approximately 38 months
PFS According to RECIST v1.1 by Baseline Serum EBI3 Status
PFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to RECIST v1.1 or death due to any cause, whichever occured first. Disease progression was defined according to RECIST v1.1 criteria, including at least a 20% increase in the sum of diameters of target lesions relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 millimeters (mm), or the appearance of one or more new lesions.
Time frame: Up to approximately 38 months
TTP According to RECIST v1.1 by Baseline Serum EBI3 Status
TTP was defined as time from study drug initiation to the occurrence of disease progression per RECIST v1.1.
Time frame: Up to approximately 38 months
OS by Baseline Serum EBI3 Status
OS was defined as the time from study drug initiation to death from any cause.
Time frame: Up to approximately 38 months
| Milestone | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Started | 30 |
| Received at least 1 dose of study treatment | 30 |
| Completed | 2 |
| Not completed | 28 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 13 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Study terminated by sponsor | 9 |
A TEAE was defined as an AE that emerged or worsened in the period from the first dose of study drug to 30 days after the last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section.
| Participants | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 30 |
PFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to RECIST v1.1 or death due to any cause, whichever occured first. Disease progression was defined according to RECIST v1.1 criteria, including at least a 20% increase in the sum of diameters of target lesions relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 millimeters (mm), or the appearance of one or more new lesions.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | 8.3 (2.0 to 14.5) |
mPFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to HCC mRECIST or death due to any cause, whichever occured first. Disease progression was defined per HCC mRECIST criteria, including at least a 20% increase in the sum of diameters of target lesions (including viable tumor diameters for typical intrahepatic target lesions and short axis diameters for nodal lesions) relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 mm.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| PFS According to Hepatocellular Carcinoma Modified RECIST (HCC mRECIST) (mPFS) | 10.3 (2.0 to 20.0) |
ORR was defined as the percentage of participants achieving complete response (CR) and partial response (PR) per RECIST v1.1. * CR: Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to \< 10 mm in short axis. * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Objective Response Rate (ORR) According to RECIST v1.1 | 39.3 (21.5 to 59.4) |
mORR was defined as the percentage of participants achieving complete response CR and PR per HCC mRECIST. * CR: Disappearance of any intratumoral arterial enhancement in all target lesions.. All pathological lymph nodes must have decreased to \< 10 mm in short axis. * PR: At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions. target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| ORR According to HCC mRECIST (mORR) | 44.4 (25.5 to 64.7) |
DoR was defined as the time from first documentation of CR or PR until the time of the first documentation of PD evaluated using RECIST v1.1 or death due to any cause.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Duration of Response (DoR) According to RECIST 1.1 | NA (12.7 to NA) |
mDoR was defined as the time from first documentation of CR or PR until the time of the first documentation of PD evaluated using HCC mRECIST or death due to any cause.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| DoR According to HCC mRECIST (mDoR) | NA (12.7 to NA) |
DCR was defined as the percentage of participants who achieved CR, PR, or SD according to RECIST v1.1 for at least 12 weeks.
| percentage of participants | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Disease Control Rate (DCR) According to RECIST v1.1 | 60.7 (40.6 to 78.5) |
mDCR was defined as the percentage of participants who achieved CR, PR, or SD according to HCC mRECIST for at least 12 weeks.
| percentage of participants | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| DCR According to HCC mRECIST (mDCR) | 63.0 (42.4 to 80.6) |
TTP was defined as time from study drug initiation to the occurrence of disease progression per RECIST v1.1.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Time to Progression (TTP) According to RECIST v1.1 | 8.1 (2.0 to 13.6) |
mTTP was defined as time from study drug initiation to the occurrence of disease progression per HCC mRECIST.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| TTP According to HCC mRECIST (mTTP) | 8.4 (2.0 to 24.6) |
OS was defined as the time from study drug initiation to death from any cause.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Overall Survival (OS) | NA (14.5 to NA) |
TTR was defined as the time from study drug initiation to initial documented objective response per RECIST v1.1.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Time to Response (TTR) According to RECIST v1.1 | 3.28 ± 1.433 |
mTTR was defined as the time from study drug initiation to initial documented objective response per HCC mRECIST.
| months | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| TTR According to HCC mRECIST (mTTR) | 2.90 ± 1.457 |
Time on therapy was defined as the time from study drug initiation to last treatment.
| weeks | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Time on Therapy | 46.7 ± 43.34 |
Baseline Serum EBI3 was collected and is reported by BOR status per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in the short axis to \<10 mm. * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression.) * Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| ng/mL | Casdozokitug + Atezolizumab + Bevacizumab: Participants With CR | Casdozokitug + Atezolizumab + Bevacizumab: Participants With PR | Casdozokitug + Atezolizumab + Bevacizumab: Participants With SD | Casdozokitug + Atezolizumab + Bevacizumab: Participants With PD | Casdozokitug + Atezolizumab + Bevacizumab: Participants With BOR Not Evaluable |
|---|---|---|---|---|---|
| Mean Serum Epstein-Barr Virus Induced Gene 3 (EBI3) Concentration by Best Overall Response (BOR) According to RECIST v1.1 | 2.117 ± 1.4513 | 2.347 ± 1.0920 | 1.572 ± 1.0121 | 2.194 ± 1.1775 | 3.203 ± 2.9529 |
PFS was defined as the time from the date of randomization to the first documented evidence of disease progression as assessed according to RECIST v1.1 or death due to any cause, whichever occured first. Disease progression was defined according to RECIST v1.1 criteria, including at least a 20% increase in the sum of diameters of target lesions relative to the smallest sum recorded during the study, with an absolute increase in the sum of diameters of at least 5 millimeters (mm), or the appearance of one or more new lesions.
| months | Casdozokitug + Atezolizumab + Bevacizumab: Participants With <= Median Baseline EBI3 Concentration | Casdozokitug + Atezolizumab + Bevacizumab: Participants With > Median Baseline EBI3 Concentration |
|---|---|---|
| PFS According to RECIST v1.1 by Baseline Serum EBI3 Status | 8.1 (1.9 to 24.6) | 8.4 (1.9 to 20.0) |
TTP was defined as time from study drug initiation to the occurrence of disease progression per RECIST v1.1.
| months | Casdozokitug + Atezolizumab + Bevacizumab: Participants With <= Median Baseline EBI3 Concentration | Casdozokitug + Atezolizumab + Bevacizumab: Participants With > Median Baseline EBI3 Concentration |
|---|---|---|
| TTP According to RECIST v1.1 by Baseline Serum EBI3 Status | 8.1 (1.9 to 24.6) | 8.4 (1.9 to NA) |
OS was defined as the time from study drug initiation to death from any cause.
| months | Casdozokitug + Atezolizumab + Bevacizumab: Participants With <= Median Baseline EBI3 Concentration | Casdozokitug + Atezolizumab + Bevacizumab: Participants With > Median Baseline EBI3 Concentration |
|---|---|---|
| OS by Baseline Serum EBI3 Status | NA (9.5 to NA) | 19.9 (14.0 to NA) |
Collected over Up to approximately 39 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Casdozokitug + Atezolizumab + Bevacizumab | 13/30 (43.3%) | 15/30 (50%) | 30/30 (100%) |
| Event | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| SepsisInfections and infestations | 2/30 |
| ColitisGastrointestinal disorders | 2/30 |
| Disease progressionGeneral disorders | 2/30 |
| Anorectal infectionInfections and infestations | 1/30 |
| CellulitisInfections and infestations | 1/30 |
| Escherichia bacteraemiaInfections and infestations | 1/30 |
| PeritonitisInfections and infestations | 1/30 |
| PneumoniaInfections and infestations | 1/30 |
| Pneumonia aspirationInfections and infestations | 1/30 |
| Duodenal perforationGastrointestinal disorders | 1/30 |
| Event | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| ProteinuriaRenal and urinary disorders | 13/30 |
| Decreased appetiteMetabolism and nutrition disorders | 12/30 |
| DiarrhoeaGastrointestinal disorders | 11/30 |
| FatigueGeneral disorders | 10/30 |
| HypertensionVascular disorders | 10/30 |
| RashSkin and subcutaneous tissue disorders | 9/30 |
| PyrexiaGeneral disorders | 7/30 |
| Platelet count decreasedInvestigations | 7/30 |
| PruritusSkin and subcutaneous tissue disorders | 7/30 |
| HeadacheNervous system disorders | 7/30 |
The Safety Analysis Set included all participants who received any amount of study drug.
| Age, Continuous(years) | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Mean | 65.0 ± 12.79 |
| Sex: Female, Male(Participants) | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Female | 7 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 20 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Serum Epstein-Barr Virus Induced Gene 3 Concentration(nanograms per milliliter (ng/mL)) | Casdozokitug + Atezolizumab + Bevacizumab |
|---|---|
| Median | 1.865 (0.32 to 5.29) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Jun 2025, 38 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion. A results delay was requested in Jun 2026.
How these figures are worked out, and which studies are left out of them.
Sponsor decision
Sponsor decision
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Casdozokitug
Coherus Oncology, Inc.